TriangleNCT02613182 · REGISTRY CONDITION SEARCH
Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- TERMINATED
- Registry last update
- 2019-05-16
The rationale for this study is to provide additional treatment with NEOD001 for subjects who complete Study NEOD001-001, and to continue to evaluate long term safety and tolerability. All subjects in the current NEOD001 trials are being dosed at 24 mg/kg, which will be continued in this study.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. Previously enrolled and treated for at least 9 months in Study NEOD001-001 2. Ability to understand and willingness to sign an informed consent form prior to initiation of any study procedures 3. Has adequate bone marrow reserve, hepatic and renal function, as demonstrated by: * Absolute neutrophil count (ANC) ≥1.0 ×109/L * Platelet count ≥75 × 109/L * Hemoglobin ≥9 g/dL * Total bilirubin ≤2 times the upper limit of normal (× ULN) * Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤3 × ULN * Estimated glomerular filtration rate ≥30 mL/minute 4. Seated systolic blood pressure 90 to 180 mmHg 5. ECOG Performance Status 0 to 2 6. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 28 days prior to the first administration of study drug and agree to use highly effective physician-approved contraception from 30 days prior to the first study drug administration to 90 days following the last study drug administration 7. Male subjects must be surgically sterile or must agree to use highly effective physician-approved contraception from 30 days prior to the first study drug administration to 90 days following the last study drug administration Exclusion Criteria: 1. Any new medical contraindication or clinically significant abnormality on physical, neurological, laboratory, vital signs, or electrocardiogram (ECG) examination (e.g., atrial fibrillation; with the exception of subjects for whom the ventricular rate is controlled) that precludes continued or initiation of treatment with NEOD001 or participation in the study 2. History of Grade ≥3 infusion-associated adverse events (AEs) or hypersensitivities to NEOD001 or any of its excipients 3. Treatment with any anticancer therapy (standard or investigational) within the 14 days prior to the first dose of study drug. In addition, subjects must have fully recovered (i.e., National Cancer Institute Common Terminology Criteria for Adverse Events \[CTCAE\] Grade 1 \[exception: subjects with prior bortezomib may have CTCAE Grade 2 neuropathy\]) from the clinically significant toxic effects of that treatment 4. Received any of the following within the specified time frame prior to the first administration of study drug: * Hematopoietic growth factors, transfusions of blood or blood products within 1 week * Major surgery within 2 weeks * Radiotherapy within 2 weeks * Transplant within 8 weeks * Investigational drug other than NEOD001 within 4 weeks * Another experimental anti-amyloid therapy other than NEOD001 within 2 years 5. Uncontrolled symptomatic orthostatic hypotension 6. Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, within 6 months prior to the first dose of study drug 7. Uncontrolled infection 8. Secondary malignancy, with the exception of: * Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer * Adequately treated stage I cancer from which the subject is currently in remission * Any other cancer from which the subject has been disease-free for ≥3 years 9. Uncontrolled human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection 10. Women who are lactating
- healthy Volunteers
- false
- sex
- ALL
- std Ages
- CHILD
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Open Label Study Drug NEOD001
- intervention Names
- Drug: NEOD001
- label
- Open Label
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Open Label
- description
- NEOD001
- name
- NEOD001
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 34
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome, or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.
- measure
- Long-term Safety and Tolerability of NEOD001
- time Frame
- From initiation of study drug through the last study visit or up to 30 days after date of last dose, whichever came first, assessed up to 24 months
Full study description
- brief Summary
- The rationale for this study is to provide additional treatment with NEOD001 for subjects who complete Study NEOD001-001, and to continue to evaluate long term safety and tolerability. All subjects in the current NEOD001 trials are being dosed at 24 mg/kg, which will be continued in this study.
- detailed Description
- The rationale for this study is to provide additional treatment with NEOD001 for subjects who complete Study NEOD001-001, and to continue to evaluate long term safety and tolerability. All subjects in the current NEOD001 trials are being dosed at 24 mg/kg, which will be continued in this study. The primary objective of the study is to evaluate long-term safety and tolerability of NEOD001 and the secondary objectives are to assess the immunogenicity of NEOD001 and to incorporate serum NEOD001 concentrations in a population pharmacokinetic (PK) analysis.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-77cfb7e0f23197979522
- requested nct id
- NCT02613182
- primary nct id
- NCT02613182
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- payload sha256
- 4b3b7047c6c61716191a7f8159f33e0b0592dd801081bbfe4c93f2b813b2868e
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-77cfb7e0f23197979522
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT02613182
- occurrences
- context exact
- NCT02613182
- end
- 11
- exact text
- NCT02613182
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Plasma Cell Neoplasms
- query disease state id
- ds-plasma-cell-neoplasms
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- source json pointer
- /studies/608/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 0873286b8afb3e2962717e75e05148533500acf087193cf161c26fb8a75108b5
Preserved source evidence · Not medical advice